Background
==========

Epilepsy is a noncommunicable chronic brain disorder that affects people all over the world. It is characterized by recurrent seizures whose frequencies may differ from less than once a year to several times a day.\[[@ref1]\] The average prevalence of epilepsy in the world is reported to be 8%,\[[@ref2][@ref3][@ref4][@ref5]\] making it one of the most prevalent neural diseases worldwide.\[[@ref6][@ref7]\] Its prevalence is rather higher in developing countries than it is in the developed countries.\[[@ref8][@ref9][@ref10]\] The prevalence of this disease in Iran is reported to be 5%, whereas it is 1% and 4% in the north and east of the country, respectively.\[[@ref11]\] Its treatment is mainly based on long-term epileptic drugs (AEDs).\[[@ref12]\] Some studies show that patients who take AEDs over a long period of time will be exposed to cardiovascular diseases, especially myocardium infarction and heart stroke. Recent studies have shown increase in the level of markers for cardiovascular risks, such as homocysteine levels, in these patients.\[[@ref13][@ref14]\]

Folic acid and vitamin B12 play prominent roles in homocysteine metabolism, and deficiency of any or both of them could lead to elevated serum homocysteine level, resulting in atherosclerosis.\[[@ref15][@ref16]\] Earlier antiepilepsy drugs such as carbamazepine, phenytoin, and phenobarbital are associated with the emergence of atherosclerosis.\[[@ref17]\] The aim of treating epilepsy is controlling the convulsions without, or with least number of, side effects.\[[@ref18][@ref19][@ref20][@ref21][@ref22]\] Levetiracetam is a new drug for the treatment of epilepsy used for partial and generalized seizures. This drug has appropriate medicinal properties that include negligible composition with protein and little effects on liver metabolism.\[[@ref23]\]

Most studies are done on earlier AEDs, and their effects are properly identified, but only few studies are being done on new drugs such as levetiracetam, and no studies have been done in this respect in Iran. This study was carried out by determining the serum level of vitamin B12, folate, and homocysteine in patients with epilepsy receiving levetiracetam.

Methods {#sec1-2}
=======

This case-control study was conducted among 68 people aged between 18 and 60 years, that included 33 (21 females and 12 males) epileptic patients who has been treated with levetiracetam monotherapy and 35 healthy people (21 females and 14 males) among whom 33 people were affected with generalized or focal epileptic seizures with no definite reasons, their disease having been diagnosed according to the International League Against Epilepsy (ILAE).\[[@ref24]\] The patients were selected from those of Massih Epileptic Research Association and the patients of a number of neurologists in private practice. The remaining 35 people were healthy individuals selected as the control group and matched with patients with respect to age and gender. After giving consent, the individuals participated in the study. The inclusion criteria were: (1) aged between 18 and 60 years; (2) At least six months of levetiracetam monotherapy; (3) Confirmed diagnosis of epilepsy by a neurologist. The exclusion criteria of the study were: (1) being a patient with any disease other than epilepsy and taking any other medications; (2) addiction to alcohol and smoking; (3) being affected by diabetes, hypertension, hypercholesterolemia, myocardial infarction, stroke, and other renal, hepatic, thyroid diseases, cancer, anemia, and mental disorders; (4) being pregnant or breast-feeding; (5) taking supplements of folate, vitamin B12; (6) being vegetarian; (7) having a history of genetic deficiencies in homocysteine, cobalamin, and folate metabolism; (8) having a ketogenic diet.

The required information from the participants, including demographic information, was obtained through a devised questionnaire. The rate of nutrients consumption was also determined using the food frequency questionnaire (FFQ) and evaluated, and the validity and reliability of the questionnaire were calculated.\[[@ref25]\]

Laboratory analysis {#sec2-1}
-------------------

A 5 mL blood sample of fasting participants was taken and centrifuged for 10 min at 6000 rpm. Serum sections were separated by centrifugation and stored at −20°C until biochemical analysis. Folate and vitamin B12 levels were measured using kits from Monobind Co. (USA) based on the competitive binding method. Homocysteine level was measured using the enzyme immunoassay kit (EIA) from Axis-Shield Co. (UK). In this method, the homocysteine bonded to protein is primarily restored in free form, and in the next stage, transformed to s-adenosyl homocysteine by the enzyme; the resulting product is measured by enzyme immunoassay method using an exclusive monoclonal antibody. The assays had sensitivities of 51.74 (pmol/L), 1.178 (nmol/L) and 0.89 (μmol/L) for vitamin B12, folate, and homocysteine, respectively.

Statistical analysis {#sec2-2}
--------------------

The one sample Kolmogorov--Smirnov test was used to analyze normality, and the Leven\'s test was used for the equality of variances. Frequency descriptive statistics (percentage) and central and dispersion indices were used for classification and data report and the covariance analysis test was applied for data analysis. SPSS statistics 22 software (IBM SPSS Statistics, Armonk, NY) was used to analyze the data; *P* values less than 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Thirty-three patients affected by epilepsy with age mean and standard deviation (30.2 ± 11.7) under monotherapy treatment with levetiracetam, and 35 healthy people (29.9 ± 11.4) were included in the study. Their demographic and clinical specifications are shown in [Table 1](#T1){ref-type="table"}. The average duration of medication intake and the daily dose of the medicine in the group of patients under treatment with levetiracetam was 2.2 ± 2.2 within a range of 6 months to 10 years and 992.4 ± 477.9 within a range of 250 to 2500 mg/day, respectively; the mean ± SD specifying the nutrients that can affect homocysteine level was determined by the FFQ questionnaire. [Table 2](#T2){ref-type="table"} presents the mean and standard deviations of the vitamin B12, and folate serum markers, and the homocysteine level in the treatment and control groups showed no significant difference. [Table 3](#T3){ref-type="table"} shows the homocysteine level, folate, and vitamin B12 conditions in two different models. Model 1 is a crude model. Education, BMI, and folate are controlled in model 2, and no significant difference was observed in the mean homocysteine serum level. The mean folate serum level in model 1 showed no significant difference, but it showed significant difference in model 2 (*P* = 0.017). The mean difference of the folate serum level between the groups of patients and healthy individuals was −2.33 in model 1, whereas it was −3.43 in model 2.

###### 

Demographic and basic clinical characteristics in levetiracetam treated and normal controls

  Variable                                Patients (*n*=33)   Healthy (*n*=35)   *P*
  --------------------------------------- ------------------- ------------------ -------
  Education *n* (%)                                                              
   School student                         8 (24.2)            7 (20)             0.94
   Elementary education                                                          
   School graduate                        14 (42.4)           14 (40)            
   Diploma                                                                       
   Higher graduate Bachelor and higher    11 (30.6)           14 (37.4)          
  Gender *n* (%)                                                                 
   Female                                 21 (63.3)           21 (60)            0.762
   Male                                   12 (36.4)           14 (40)            
  Age (Y)                                                                        
   Mean±SD                                30.2±11.7           29.9±11.4          0.9
  BMI (kg/m^2^)                                                                  
   Mean±SD                                24.51±5.56          25.3±4.34          0.486
  Duration of using the medicine (year)                                          
   Mean±SD                                2.24±2.21           \-                 \-
  Dosage of medicine (mg/day)                                                    
   Mean±SD                                992.42±477.97       \-                 \-
  Intake of vitamin B12 (μg/day)                                                 
   Mean±SD                                3.21±3.22           3.62±5             0.688
  Intake of Folate\* (μg/day)                                                    
   Mean±SD                                212.6±92            252.5±100.56       0.093

\*: *P* value was calculated for qualitative variable: Chi-square for quantitative variable: independent *t* test

###### 

Serum level of vitamin B12, folic acid and homocysteine in levetiracetam treated and normal controls

  Variable                      Patient       Healthy         *P*
  ----------------------------- ------------- --------------- -------
  Serum homocysteine (μmol/L)                                 
   Mean±SD                      10.06±4.86    10.02±3.16      0.967
  Serum folate (nmol/L)                                       
   Mean±SD                      21.55±11.22   26.85±12.53     0.071
  Serum vitamin B12 (Pmol/L)                                  
   Mean±SD                      281.2±99.04   326.22±108.32   0.079

###### 

Analysis of the serum condition in homocysteine, folate, and vitamin B12 in two different models

  Variable                      F-test *P*   Difference *P*    95% confidence interval
  ----------------------------- ------------ ----------------- -------------------------
  Serum homocysteine (μmol/L)                                  
   Model 1 \*                   0.967        0.041 (0.967)     1.936 to 2.517
   Model 2 \*\*                 0.703        1.6 (0.336)       −1.68 to 4.84
  Serum folate (nmol/L)                                        
   Model 1                      0.071        −2.33 (0.71)      −4.887 to 2.9
   Model 2                      0.017        −3.43 (0.15)      −8.16 to 1.26
  Serum vitamin B12 (pmol/L)                                   
   Model 1                      0.079        −61.018 (0.079)   −1129.259 to 7.224
   Model 2                      0.054        −41.77 (0.529)    −173.8 to 90.25

\*: Crude, \*\*: Controlled for BMI, education, folate intake

The mean vitamin B12 serum level in model 2 is very close to the significance level (*P* = 0.054), with regards to reduction of 61 units in model 1 and 41 units in model 2 in the study group compared to the control group.

Discussion {#sec1-4}
==========

According to [Table 3](#T3){ref-type="table"}, we controlled the effects of education, BMI, and folate in model 2 in our study, and it was observed that the *P* value approached the significance level in both models, such that it was significant for folate, and quite close to the significance level for vitamin B12. It can be said that diet in individuals in anthropometric conditions and even educational status can affect significance. Nutritional conditions have not been specified in previous studies, but it should be noted that diet can be effective on the serum conditions of folate, vitamin B12, and homocysteine, as observed for folate and vitamin B12 in this study.

Previous studies show that patients under long-term treatment with previous AEDs are at a higher risk of increased homocysteine and reduced folate levels than normal people.\[[@ref26][@ref27][@ref28][@ref29][@ref30]\] The nutritional circumstances of vitamin B12, folate, and Hcy was measured in the patients under treatment with levetiracetam for a minimum of 6 months. Levetiracetam is a new medicine that is quite distinct as compared to other antiepileptic medicines due to its pharmacological properties and practical mechanisms, although its mechanism is not yet properly known.\[[@ref31]\] It was shown in a study by Aydin and Varoglu that using levetiracetam in epileptic patients cannot be related to hyperhomocysteinemia or reduction of vitamin B12 and folate.\[[@ref32]\] Another study done to analyze homocysteine levels in epileptic patients under treatment with new antiepileptic medication showed that lamotrigine and levetiracetam levetiracetam do not increase homocysteine.\[[@ref33]\]

Previous AED medicines affect homocysteine metabolism by reducing methylenetetrahydrofolate reductase (MTHFR) activities; these drugs can intervene with the absorption and metabolism of folate.\[[@ref34]\] The relation between homocysteine and epilepsy is still not known.\[[@ref35]\] However, most studies have shown that using earlier medicines such as carbamazepine and valproic acid increases homocysteine levels,\[[@ref15][@ref16][@ref33]\] and long-term treatment with these medicines reduces the storage capabilities of the liver for vitamin B12.\[[@ref36]\] In fact, it can be said that these medicines stimulate the P450 (CYP) of liver cells.\[[@ref17]\] Recent studies have shown that increase in homocysteine level can be observed in patients who use the newer drugs (new-AEDs) such as topitamate and oxacarbamazepine.\[[@ref33]\] The increase in atherogenicity created by the new medicines cannot be entirely due to the CYP system or the deficiency of cofactors for homocysteine metabolism; there are additional mechanisms that are not still known.\[[@ref17]\] Nevertheless, the present and previous studies show that people under monotherapy treatment with levetiracetam have a normal homocysteine level.\[[@ref34][@ref35][@ref36][@ref37]\] In any case, in the study by Kim *et al.*, patients under levetiracetam treatment showed significant increase in their homocysteine level, whereas unchangeable levels were observed for folate and vitamin B12.\[[@ref17]\]

One of the limitations in our study was the few number of patients; Linnebank *et al.* recruited 2730 patients,\[[@ref36]\] and that carried out by Belcastro *et al.* included 480 patients.\[[@ref32]\] Also, we had no information about the status of the patients before levetiracetam consumption. Thus, we could not compare the factors with or without treatment by anti-epilepsy medicines. Finally, we did not observe the long-term effects of levetiracetam.

The strong point of our study was the investigation of the patient\'s diet, which was done using the FFQ, and was shown to be effective on the significance or insignificance of the serum factors.

Conclusions {#sec1-5}
===========

Our findings show that treatment of epileptic patients exposed to the risk of cardiovascular diseases with the new medicine levetiracetam is possible as the medicine had no effects on homocysteine levels. However, patients who take high doses of the medicine on a long-term basis and patients harboring the risk factors such as obesity who have a family history of cardiovascular diseases should be under observation for the assessment of the relevant markers (vitamin B12, folate, and homocysteine). Another significant point is the diet of the patient as reduction in the level of folate and vitamin B12 in patients, especially those taking the medicine on a long-term basis in high dosages may be due to an inadequate diet; this can be compensated for by diet modification or the use of supplements where necessary.
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